HIV growth in infected people is now partially controlled by anti-retroviral therapies. If we are to eliminate HIV, more effective means of countering the virus are needed. One conceivable mode of therapy is to program CD4-positive T cells, the main cells that grow HIV in the body, to make a molecule that would prevent HIV from growing in the cells. We have called this """"""""intracellular immunization."""""""" We have successfully demonstrated such an approach using a lentivirus vector to carry into the cell genome a cassette that can specify synthesis of a small RNA able to interfere with the production of the cellular receptor for HIV, CCR5. We now propose to develop this idea further. We will optimize the interfering RNA so that it is as efficient as Possible at inhibiting CCR5 synthesis. This will be done by an efficient but comprehensive tiling process. Because HIV can mutate so that it no longer requires CCR5, we need to hit multiple targets. Thus we will develop vectors with multiple cassettes, some against the viral genome. These too will have to be optimized. Then the vectors must be tested in human T cells in culture. Ultimately, their safety and efficacy in humans will have to be investigated. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI060479-02
Application #
6874327
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Voulgaropoulou, Frosso
Project Start
2004-04-01
Project End
2006-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
2
Fiscal Year
2005
Total Cost
$162,000
Indirect Cost
Name
California Institute of Technology
Department
Type
Schools of Arts and Sciences
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125